An emerging biotech developing an ATMP for a rare disease was blindsided by a last-minute FDA meeting request, threatening to upend their IND timeline. With no time to spare, the company had to act fast. What unfolded next was a high-stakes sprint involving regulatory agility, strategic coordination, and expert intervention.
Discover the full case study here: https://voisinconsulting.com/case_study/enhanced-clinical-pathways-mastering-challenges-with-comprehensive-expertise-emergency-management/ to see how VCLS helped the client to navigate the challenge, and what it means for ATMP developers facing similar hurdles.